Business, energy, technology, markets and global industry news from Business News Today

LIVMARLI

PharmaDeviceNews LIVMARLI
Editorial infographic highlighting Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Phase 3 EXPAND trial, featuring liver illustrations, clinical research graphics and an October 12 results announcement, with emphasis on evaluating itching relief in additional rare liver diseases.
Pharma & Biotech

Mirum’s EXPAND study tests maralixibat for treatment-resistant cholestatic pruritus

Mirum will reveal LIVMARLI EXPAND Phase 3 results on October 12, testing whether maralixibat can treat itching in additional rare liver diseases.

Read More
Representative image: Rare liver disease research is gaining fresh attention as Mirum Pharmaceuticals reports new EASL 2026 data on volixibat, brelovitug, and LIVMARLI.
Pharma & Biotech

Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update

Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.

Read More
Representative image: Clinical researchers review liver disease imaging and trial data as Mirum Pharmaceuticals prepares to share VISTAS study results for volixibat in primary sclerosing cholangitis.
Pharma & Biotech

Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?

Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.

Read More